Multiple Myeloma | Oncology Today with Dr Neil Love: Managing Transplant-Ineligible Newly Diagnosed Multiple Myeloma

Featuring an interview with Dr Saad Zafar Usmani, including the following topics: Determining transplant eligibility for patients with newly diagnosed multiple myeloma (MM); treatment for transplant-eligible patients who decline transplant (0:00) Assessing frailty in patients with MM; underrepresentation of older patients in clinical trials (5:32) Selection of first-line therapy for transplant-ineligible patients with MM (10:55) Emerging data with daratumumab and lenalidomide/bortezomib/dexamethasone (RVd) for patients with MM; defining high-risk MM (16:56) Outcomes from the real-world community-based TOURMALINE US-MM6 trial evaluating ixazomib-based induction treatment (20:19) Efficacy and safety findings from the ENDURANCE trial comparing KRd (carfilzomib/lenalidomide/dexamethasone) to RVd (25:28) Optimal management of proteasome inhibitor-associated neuropathy; novel and emerging therapies for MM (28:52) Management of toxicities and other practical issues associated with CAR (chimeric antigen receptor) T-cell therapy for MM (34:41) CME information and select publications